Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study to Compare Toripalimab Combined With Lenvatinib Versus Placebo Combined With Lenvatinib as the 1st-line Therapy for Advanced HCC
Conditions
Interventions
Toripalimab combined with Lenvatinib
Placebo combined with Lenvatinib
Locations
22
China
Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command
Nanjing, Jiangsu, China
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica
Milan, Italy
IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori
Naples, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
A.O.U. Citta della Salute e della Scienza di Torino
Tortona, Italy
AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma
Verona, Italy
Start Date
June 29, 2020
Primary Completion Date
December 31, 2025
Completion Date
September 1, 2026
Last Updated
December 9, 2025
NCT07493044
NCT07039201
NCT06737913
NCT07282509
NCT01101906
NCT04212221
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions